Menu

Peer-Review Fraud Scheme Uncovered in China

The Chinese government finds almost 500 researchers guilty of misconduct in relation to a recent spate of retractions from a cancer journal.

Jul 31, 2017
Bob Grant

© BRYAN SATALINOAfter a sweeping research misconduct investigation, China’s Ministry of Science and Technology (MST) has found nearly 500 researchers guilty of engaging in a peer-review fraud scam. Announced late last week (July 27), MST’s findings indicate that 486 scientific paper authors engaged, to some degree, in a scheme to nominate either fictitious or paid peer reviewers who would write positive reviews of their manuscripts.

“We should eradicate the problem from its roots,” He Defang, director of MST’s regulatory division in Beijing, tells Science.

MST is meting out stiff penalties to the guilty researchers. These range from suspending their research projects and canceling grants to rescinding promotions or even harsher retribution. “They will face punishment according to the Communist Party of China discipline regulations and the regulations on personnel from public institutions,” He told Chinese news outlet Xinhua.

The nature of the scam is not unprecedented, with Chinese authors being accused of similar practices in the recent past.

See “The Past and Present of Reseach Integrity in China

The investigation was sparked by the retraction of 107 papers—many of which were authored by Chinese scientists and were published between 2012 and 2016—from Tumor Biology in April. The MST found that of the 521 authors it investigated, 11 were innocent, and 24 are still under investigation. The agency also determined that nine of those papers contained completely faked data and that 95 of the papers involved third parties providing phony reviews.

Of the 486 researchers found guilty of misconduct, 314 were characterized as “neglecting the management of academic achievements and paper publications,” according to Xinhua.

Many in the scientific community within China are praising the government’s efforts to root out fraudsters, including its stated zero-tolerance stance on research misconduct. MST’s recent disciplinary action “reminds us that 'zero tolerance' toward academic dishonesty needs further strengthening, and the actions by the Chinese government are very timely,” Yong-Guan, a biogeochemist at the Institute of Urban Environment in Xiamen, China, tells Science.

(Hat tip to Retraction Watch)

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance. Used together, Bio-Rad’s system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.